{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:47:00Z","timestamp":1793119620837,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000672","name":"Pathological Society of Great Britain and Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020400","name":"John Black Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.annonc.2026.05.708","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:31:42Z","timestamp":1780720302000},"page":"1334-1344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6488-7315","authenticated-orcid":false,"given":"C.T.A.","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H-C.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Grist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Croucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7359-7114","authenticated-orcid":false,"given":"A.","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.Y.T.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Santos Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Todorovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Thakali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wingate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zakka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wetterskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Nowakowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Amos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Berney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-1371","authenticated-orcid":false,"given":"M.R.","family":"Sydes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2827-6634","authenticated-orcid":false,"given":"L.C.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.G.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.W.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0398-6018","authenticated-orcid":false,"given":"C.J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.L.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.B.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Esteva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.D.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-7983","authenticated-orcid":false,"given":"G.","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2026.05.708_bib1","author":"Spratt","year":"2025"},{"issue":"10323","key":"10.1016\/j.annonc.2026.05.708_bib2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"The Lancet"},{"issue":"Suppl 5","key":"10.1016\/j.annonc.2026.05.708_bib3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1200\/JCO.2025.43.5_suppl.367","article-title":"Real-world discontinuation and efficacy data of abiraterone acetate\/prednisone (AAP) plus androgen deprivation therapy and radiotherapy in localized prostate cancer","volume":"43","author":"Di Costanzo","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.05.708_bib4","doi-asserted-by":"crossref","first-page":"S1743","DOI":"10.1016\/j.annonc.2025.09.102","article-title":"LBA86 randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)","volume":"36","author":"Nguyen","year":"2025","journal-title":"Ann Oncol"},{"issue":"Suppl 15","key":"10.1016\/j.annonc.2026.05.708_bib5","doi-asserted-by":"crossref","first-page":"TPS5087","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5087","article-title":"ATLAS: a randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy","volume":"34","author":"Sandler","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"10.1016\/j.annonc.2026.05.708_bib6","doi-asserted-by":"crossref","first-page":"TPS385","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS385","volume":"38","author":"Niazi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.05.708_bib7","first-page":"485","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.annonc.2026.05.708_bib8","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/pros.24184","article-title":"Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores","volume":"81","author":"Wenzel","year":"2021","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.annonc.2026.05.708_bib9","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.juro.2017.12.048","article-title":"Contemporary incidence and outcomes of prostate cancer lymph node metastases","volume":"199","author":"Bernstein","year":"2018","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.708_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41746-022-00613-w","article-title":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","volume":"5","author":"Esteva","year":"2022","journal-title":"NPJ Digit Med"},{"issue":"8","key":"10.1016\/j.annonc.2026.05.708_bib11","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300023","article-title":"Artificial intelligence predictive model for hormone therapy use in prostate cancer","volume":"2","author":"Spratt","year":"2023","journal-title":"NEJM Evidence"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.708_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s44387-025-00044-4","article-title":"The AI revolution: how multimodal intelligence will reshape the oncology ecosystem","volume":"1","author":"Dellamonica","year":"2025","journal-title":"NPJ Artif Intell"},{"issue":"32","key":"10.1016\/j.annonc.2026.05.708_bib13","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1200\/JCO.24.00365","article-title":"Development and validation of an artificial intelligence digital pathology biomarker to predict benefit of long-term hormonal therapy and radiotherapy in men with high-risk prostate cancer across multiple phase III trials","volume":"43","author":"Armstrong","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2026.05.708_bib14","volume":"7","author":"Parker","year":"2025","journal-title":"Lancet Digit Health"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.708_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1745-6215-10-39","article-title":"Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial","volume":"10","author":"Sydes","year":"2009","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.708_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1745-6215-13-168","article-title":"Flexible trial design in practice stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial","volume":"13","author":"Sydes","year":"2012","journal-title":"Trials"},{"key":"10.1016\/j.annonc.2026.05.708_bib17","article-title":"Prostate cancer risk stratification in NRG oncology phase III randomized trials using multimodal deep learning with digital histopathology","volume":"8","author":"Tward","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.05.708_bib18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.eururo.2024.06.019","article-title":"Meta-analysis of individual patient-level data for a multimodal artificial intelligence biomarker in high-risk prostate cancer: results from six NRG\/RTOG phase 3 randomized trials","volume":"86","author":"Spratt","year":"2024","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.annonc.2026.05.708_bib19","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.euo.2024.01.004","article-title":"External validation of a digital pathology-based multimodal artificial intelligence architecture in the NRG\/RTOG 9902 phase 3 trial","volume":"7","author":"Ross","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.05.708_bib20","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/JU.0000000000004435","article-title":"An artificial intelligence-digital pathology algorithm predicts survival after radical prostatectomy from the prostate, lung, colorectal, and ovarian cancer trial","volume":"213","author":"Li","year":"2025","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.annonc.2026.05.708_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/PO-24-00653","article-title":"Digital pathology\u2013based multimodal artificial intelligence scores and outcomes in a randomized phase III trial in men with nonmetastatic castration-resistant prostate cancer","author":"Feng","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.05.708_bib22","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/1078-0432.CCR-24-3656","article-title":"Validation of a digital pathology\u2013based multimodal artificial intelligence biomarker in a prospective, real-world prostate cancer cohort treated with prostatectomy","volume":"31","author":"Bjartell","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.05.708_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110618","article-title":"Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic castration-sensitive prostate cancer","volume":"202","author":"Wang","year":"2025","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.05.708_bib24","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.euo.2024.11.009","article-title":"Digital pathology\u2013based artificial intelligence biomarker validation in metastatic prostate cancer","volume":"8","author":"Markowski","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.708_bib25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/aipo.2024.0004","article-title":"Analytical validation of a clinical grade prognostic and classification artificial intelligence laboratory test for men with prostate cancer","volume":"1","author":"Gerrard","year":"2024","journal-title":"AI Precis Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.708_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2024.04.038","article-title":"Refining risk stratification of high-risk and locoregional prostate cancer: a pooled analysis of randomized trials","volume":"87","author":"Ravi","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2026.05.708_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2025.12.007","article-title":"Development and validation of a multimodal artificial intelligence-derived digital pathology\u2013based biomarker predicting metastasis among patients with biochemical recurrence after radical prostatectomy in NRG\/RTOG trials","author":"Morgan","year":"2025","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.annonc.2026.05.708_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/CCI-24-00284","article-title":"Assessing algorithmic fairness with a multimodal artificial intelligence model in men of African and non-African origin on NRG oncology prostate cancer phase III trials","author":"Roach","year":"2025","journal-title":"JCO Clin Cancer Inform"},{"issue":"10231","key":"10.1016\/j.annonc.2026.05.708_bib29","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"10071","key":"10.1016\/j.annonc.2026.05.708_bib30","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.708_bib31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.euo.2024.11.006","article-title":"Baseline nodal status on 68Ga-PSMA-11 positron emission tomography\/computed tomography in men with intermediate- to high-risk prostate cancer is prognostic for treatment failure: follow-up of the proPSMA trial","volume":"9","author":"Hofman","year":"2026","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.05.708_bib32","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41391-025-00983-8","article-title":"Abiraterone for \u201cSTAMPEDE-Like\u201d cohort of high-risk prostate cancer in the PSMA-PET era: too much, too early?","volume":"28","author":"Murthy","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"13","key":"10.1016\/j.annonc.2026.05.708_bib33","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.3390\/diagnostics13132144","article-title":"Department wide validation in digital pathology experience from an academic teaching hospital using the UK Royal College of Pathologists\u2019 Guidance","volume":"13","author":"Kelleher","year":"2023","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.annonc.2026.05.708_bib34","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/jclinpath-2017-204808","article-title":"Digital pathology access and usage in the UK: results from a national survey on behalf of the National Cancer Research Institute\u2019s CM-Path initiative","volume":"71","author":"Williams","year":"2018","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.708_bib35","article-title":"Digital Pathology in South Africa: a survey and cross-sectional analysis of the current level of use and comparison with the international community","volume":"2025","author":"Eloff","year":"2025","journal-title":"Int J Telemed Appl"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.708_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13000-025-01610-9","article-title":"An update on applications of digital pathology: primary diagnosis; telepathology, education and research","volume":"20","author":"Zia","year":"2025","journal-title":"Diagn Pathol"},{"issue":"6","key":"10.1016\/j.annonc.2026.05.708_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269192","article-title":"Cost-utility analysis of adding abiraterone acetate plus prednisone\/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: lifetime decision model based on STAMPEDE trial data","volume":"17","author":"Clarke","year":"2022","journal-title":"PLOS ONE"},{"issue":"Suppl 6","key":"10.1016\/j.annonc.2026.05.708_bib38","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/JCO.2023.41.6_suppl.358","article-title":"Cost-effectiveness of abiraterone acetate for high-risk non-metastatic prostate cancer","volume":"41","author":"Lester-Coll","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.05.708_bib39","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2025.11.009","article-title":"ESMO basic requirements for AI-based biomarkers in oncology (EBAI)","volume":"37","author":"Aldea","year":"2026","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426009142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426009142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:43:04Z","timestamp":1789760584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426009142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0923753426009142"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.05.708","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.05.708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}